Results 121 to 130 of about 17,680 (157)

Phase Ib study of berzosertib, carboplatin, gemcitabine, and pembrolizumab in patients with squamous nonsmall lung cancer (ETCTN 10313). [PDF]

Oncologist
Villaruz LC, Schluger B, Wang H, Ohr J, Petro D, Fuld AD, Herzberg B, Dawar R, Nieva J, Ruiz J, Christner SM, Holleran JL, Bakkenist CJ, Gore S, Beumer JH.   +14 more
europepmc   +1 more source

Exploring the Landscape of Immune Checkpoint Inhibitor-Induced Adverse Events Through Big Data Mining of Pan-Cancer Clinical Trials. [PDF]

Oncologist
Fadlullah MZH, Lin CN, Coleman S, Young A, Naqash AR, Hu-Lieskovan S, Tan AC.   +6 more
europepmc   +1 more source

Clinical and pathological outcomes of deferred nephrectomy in patients with metastatic and locally advanced RCC after immune checkpoint inhibitors. [PDF]

Oncologist
do Amaral PS, Beckermann KE, Gordetsky JB, Chang SS, Joyce DD, Schaffer K, Luckenbaugh AN, Lambrecht MA, Ryan EG, Barocas DA, Moses KA, Rini BI.   +11 more
europepmc   +1 more source

Immunological and Safety Considerations When Selecting the Dose Formulation of a Purified Inactivated Zika Virus Vaccine (PIZV). [PDF]

Microorganisms
Acosta CJ, Nordio F, Kpamegan E, Moss KJ, Kumar P, Hirata K.   +5 more
europepmc   +1 more source

The Portormin (Dunbeath) Runestone

Futhark: International Journal of Runic Studies, 2016
Martin Findell
doaj  

Runes and Editors: The Changing Face of Corpus Editions

Futhark: International Journal of Runic Studies, 2010
Michael P. Barnes
doaj  

N 244 Helland II: A Topsy-turvy Runestone

Futhark: International Journal of Runic Studies, 2013
James E. Knirk
doaj